Bayer, Novartis Near Settlement Over MS Drug

Law360, New York (January 12, 2007, 12:00 AM EST) -- Pharmaceutical companies Novartis AG and Bayer AG may soon be settling their differences over the production and marketing of multiple sclerosis drug Betaseron.

The companies jointly asked a court in California to postpone a deadline from Jan. 16 to Feb. 20 so they could continue settlement talks, the Financial Times Deutschland reported.

Currently, Bayer unit Schering and Novartis unit Chiron have a licensing deal over Betaseron set to end in 2008. Chiron exclusively produces the drug in the United States for Schering and receives a 22.5%...
To view the full article, register now.